Physician profile
John Yacoub
NPI 1417980483
$14,493.80
in general payments reported to CMS, 2019-2025
29 companies · $4,642 in 2025
The $4,642 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,728 · 2020: $494 · 2021: $1,733 · 2022: $1,220 · 2023: $2,031 · 2024: $1,645 · 2025: $4,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273 · Travel and Lodging: $3,975 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,273.18 |
| Travel and Lodging | $3,974.91 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,455.37 | 2019-2025 | Ingevity+, Emblem Mri S-Icd, S-Icd System Magnet |
| Medtronic, INC. | $2,419.39 | 2021-2025 | Symplicity G3, Onyx Frontier, Signia |
| Abbott Laboratories | $2,201.95 | 2019-2023 | Cardiomems, Gallant |
| Philips North America LLC | $1,637.89 | 2022-2025 | Igt Devices Undivided, (Bs2) Lm Undivided, (9520) Igt Devices Undivided |
| Biotronik INC. | $1,593.74 | 2021-2025 | Selectra, Solia, Acticor 7 Vr-T Dx |
| E.R. Squibb & Sons, L.L.C. | $786.57 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $748.00 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $315.03 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $295.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $224.43 | 2022-2025 | Verquvo |
| Abiomed | $199.21 | 2025 | |
| Cardiovascular Systems INC. | $183.11 | 2022 | |
| W. L. Gore & Associates, INC. | $145.36 | 2019 | |
| Medtronic Vascular, INC. | $142.86 | 2019 | |
| Pfizer INC. | $129.10 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $126.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.93 | 2019 | |
| Endologix LLC | $122.03 | 2024 | Endocross Device, Torus Stent Graft System |
| Terumo Medical Corporation | $109.58 | 2021 | |
| Amgen INC. | $102.80 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $88.64 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $78.37 | 2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $67.15 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.43 | 2019-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $45.27 | 2024 | Arcalyst |
| Novo Nordisk INC | $44.35 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2022-2024 | Jardiance |
| Cvrx, INC. | $18.21 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yacoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.